Open-label, fase 1- dosisescalatie en uitbreidingsstudie van IMGN151 (een anti-FRα geneesmiddel-antilichaamconjugaat) bij volwassen patiënten met recidiverende gynaecologische kankers. Samenvatting De studie betreft een Fase1, open-label dosis-escalatie- en uitbreidingsstudie,…
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-Resistant Prostate Cancer Samenvatting Xaluritamig is een op STEAP1 (six transmembrane…
Studiecoördinator Bij vragen of verwijzingen graag contact opnemen met de studiecoördinator. Prof.dr. A.K.L. Reyners Afdeling Medische Oncologie Tel.: 050 3612821 (secretariaat Oncologie) E-mail: a.k.l.reyners@umcg.nl
Fase 2 MK-4280A -co-formulatie van Favezelimab (MK-4280) en Pembrolizumab (MK-3475) – bij geselecteerde solide tumoren (Cohort A:cSCC / Cohort B: pMMR EC) A randomized, double-blind, placebo-controlled phase 2,…
Studiecoördinator Dr. S.F. Oosting Afdeling Medische Oncologie Tel.: 050 3612821 (secretariaat Oncologie) E-mail: s.f.oosting@umcg.nl
OPEN LABEL PHASE 2 BASKET TRIAL WITH ATEZOLIZUMAB AND TIRAGOLUMAB IN SOLID TUMORS: TIRACAN Samenvatting In deze studie wordt de effectiviteit en veiligheid van de combinatie behandeling met…
A Phase 3 Trial of Fianlimab (REGN3767, anti-LAG-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma Samenvatting Dit is een fase…
(Peak) A Phase 3 Randomized, Open-label, Multicenter Clinical Study of CGT9486+Sunitinib vs Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors Samenvatting Dit is een…
ANZadapt studie Phase II randomised controlled trial of patient-specific adaptive versus continuous Abiraterone or eNZalutamide in metastatic castration-resistant prostate cancer: the ANZadapt study Samenvatting De ANZadapt studie is…
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic…
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose…
A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) plus Pembrolizumab (MK- 3475) Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment…
Safe Stop IPI-NIVO Trial: Early Discontinuation of Nivolumab Upon Achieving a (Confirmed) Complete or Partial Response in Patients With Irresectable Stage III or Metastatic Melanoma Treated With First-line…
A Phase I Study to Assess Biodistribution of 89Zr-CB307 in PSMA+ and PSMA-Tumour Lesions Eudractnummer: 2021-006256-13 CB307 is een trispecifieke Humabody® gericht op CD137; PSMA; en humaan serumalbumine…
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination with Abiraterone plus Prednisone in Men with High-Risk Metastatic Hormone-Sensitive Prostate Cancer EU trial number: 2022-500461-28-06 Samenvatting…
A 3 arm randomized study on health-related quality of life of elderly patients with advanced soft tissue sarcoma undergoing doxorubicin every three weeks or doxorubicin weekly or cyclophosphamide…
A Phase 1a/1b Study exploring the safety and tolerability of INCB081776 +/- retifanlimab in participants with advanced malignancies Protocol: INCB 81776-101 EudraCT Number: 2020-004867-26 Een Fase 1a/1b, open label…
A Phase 1a/1b Study exploring the safety and tolerability of INCB081776 +/- retifanlimab in participants with advanced malignancies Protocol: INCB 81776-101 EudraCT Number: 2020-004867-26 Een Fase 1a/1b, open label…
A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT)Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy,…